These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Alterations of tear neuromediators in dry eye disease. Lambiase A, Micera A, Sacchetti M, Cortes M, Mantelli F, Bonini S. Arch Ophthalmol; 2011 Aug; 129(8):981-6. PubMed ID: 21825181 [Abstract] [Full Text] [Related]
24. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Kinoshita S, Awamura S, Nakamichi N, Suzuki H, Oshiden K, Yokoi N, Rebamipide Ophthalmic Suspension Long-term Study Group. Am J Ophthalmol; 2014 Mar; 157(3):576-83.e1. PubMed ID: 24246575 [Abstract] [Full Text] [Related]
28. A comparative study to assess the clinical use of Fluorescein Meniscus Time (FMT) with Tear Break up Time (TBUT) and Schirmer's tests (ST) in the diagnosis of dry eyes. Kallarackal GU, Ansari EA, Amos N, Martin JC, Lane C, Camilleri JP. Eye (Lond); 2002 Sep; 16(5):594-600. PubMed ID: 12194075 [Abstract] [Full Text] [Related]
29. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome. Demiryay E, Yaylali V, Cetin EN, Yildirim C. Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057 [Abstract] [Full Text] [Related]
31. Increase in central corneal thickness in dry and normal eyes with application of artificial tears: a new diagnostic and follow-up criterion for dry eye. Karadayi K, Ciftci F, Akin T, Bilge AH. Ophthalmic Physiol Opt; 2005 Nov; 25(6):485-91. PubMed ID: 16343124 [Abstract] [Full Text] [Related]
32. OCT assessment of tear meniscus after punctal occlusion in dry eye disease. Ibrahim OM, Dogru M, Kojima T, Matsumoto Y, Wakamatsu TH, Tsubota K, Fujishima H. Optom Vis Sci; 2012 May; 89(5):E770-6. PubMed ID: 22466101 [Abstract] [Full Text] [Related]
33. Prospective evaluation of hypromellose 2% for punctal occlusion in patients with dry eye. Capita L, Chalita MR, dos Santos-Neto LL. Cornea; 2015 Feb; 34(2):188-92. PubMed ID: 25514700 [Abstract] [Full Text] [Related]
35. Tear osmolarity measurements in dry eye related to primary Sjögren's syndrome. Utine CA, Bıçakçıgil M, Yavuz S, Çiftçi F. Curr Eye Res; 2011 Aug; 36(8):683-90. PubMed ID: 21780917 [Abstract] [Full Text] [Related]
36. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Liew SH, Nichols KK, Klamerus KJ, Li JZ, Zhang M, Foulks GN. Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048 [Abstract] [Full Text] [Related]
37. [Clinical study of the effectiveness of a preservative-free tear substitute]. Brewitt H, Joost P. Klin Monbl Augenheilkd; 1991 Sep; 199(3):160-4. PubMed ID: 1753667 [Abstract] [Full Text] [Related]
38. Efficacy of punctum plug treatment in short break-up time dry eye. Kaido M, Ishida R, Dogru M, Tamaoki T, Tsubota K. Optom Vis Sci; 2008 Aug; 85(8):758-63. PubMed ID: 18677228 [Abstract] [Full Text] [Related]